Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Investors need to pay close attention to Catalent (CTLT) stock based on the movements in the options market lately.

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The first notable agency action in 2024 is the FTC’s Second Request in Novo Holding’s proposed $16.5 billion acquisition of Catalent, a life sciences contract manufacturer. 1 The agency’s interest in ...

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.4 which represents a decrease of $-0.32 or -0.53% from the prior close of $60.72. The stock opened at $60.7 and touched a ...

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns. Catalent Inc. (NYSE: CTLT) has seen a rise in its stock price by 0.03 in ...

Catalent Inc (CTLT) stock saw a decline, ending the day at $60.7 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.96. The stock opened at $60.6 and touched a low of $60.49 ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

Aug 30 (Reuters) - Catalent (CTLT.N), opens new tab said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".